Adjuvant Chemotherapy for Locally Advanced Cervical Cancer

Summary

Data of survival benefit from adjuvant chemotherapy (ACT) after concurrent chemoradiation (CCRT) for locally advanced cervical cancer (LACC) are still limited and inconsistent. We will investigate if ACT has survival benefit over CCRT alone.

Conditions

• Uterine Cervical Cancer

Interventions

RADIATION

Pelvic radiation

Radiation: * Pelvic radiation 1.8 Gy/ day, 5 days/ week, 6 weeks * Brachytherapy 30-35 Gy for 4-5 times

DRUG

Cisplatin

Cisplatin 40 mg/m2 i.v.

DRUG

Paclitaxel

Paclitaxel 175 mg m2 i.v.

DRUG

Carboplatin

Carboplatin AUC 5 i.v.

Sponsors & Collaborators

• National Research Council of Thailand

  collaborator OTHER_GOV

• Navamindradhiraj University

  collaborator OTHER

• Chiang Mai University

  collaborator OTHER

• Prince of Songkla University

  collaborator OTHER

• Bhumibol Adulyadej Hospital

  collaborator OTHER

• Lopburi Cancer Hospital

  collaborator UNKNOWN

• Ubonratchathani Cancer Hospital

  collaborator UNKNOWN

• Udonthani Cancer Hospital

  collaborator UNKNOWN

• Chonburi Cancer Hospital

  collaborator UNKNOWN

• Lampang Cancer Hospital

  collaborator OTHER

• Health Intervention and Technology Assessment Program

  collaborator UNKNOWN

• Rajburi Hospital

  collaborator UNKNOWN

• Siriwan Tangjitgamol, MD

  lead OTHER

Principal Investigators

• Siriwan Tangjitgamol, MD · Navamindradhiraj University

• Vichan Lordvithaya, MD · Chiang Mai University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

70 Years

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2014-01-31

Primary Completion

2018-01-31

Completion

2019-01-31

Countries

• Thailand

Study Locations